Gilead remdesivir results mixed in moderate COVID-19 patients

Click For Larger Image & Read More
Gilead remdesivir results mixed in moderate...
 © In-Cyprus 2020
 

Gilead Sciences Inc said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate COVID-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10-days did not.

Gilead shares fell about 2.7 percent in early trading.

Remdesivir is being closely watched after the U.S. Food and Drug Administration granted emergency use authorization last month, citing results from another study run by the National Institutes of Health that showed the drug...


Read all latest: Cyprus Coronavirus News Updates - Live

This article was automatically added to our system 1-6-2020

Gilead remdesivir results mixed in moderate COVID-19 patients


The contents of this article including any associated images are © In-Cyprus 2020
Views & opinions expressed in this article are those of the author and/or In-Cyprus .

Advertise Here

  Trending Cyprus News

Advertise Here

Article Tags: gilead, remdesivir, results, mixed, moderate, covid, patients,